We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Iconic Labs CEO; Tiziana Hires Executive Director

Fri, 05th Feb 2021 12:28

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and not separately reported by Alliance News:

----------

Iconic Labs PLC - London-based media company - Appoints Sarah Dees as chief executive with immediate effect. Dees has a "wealth of management and fundraising experience" across a variety of sectors including financial technology, banking, live events and natural resources. "I am delighted to have the opportunity to lead Iconic Labs through the next phase of its development following the recent board changes. I will be prioritising early dialogue with OTT Holdings, alongside existing shareholders and lenders," Dees says.

On Monday, Iconic Labs received termination notices for management service agreements with Greencastle Capital for TheLondonEconomic, with management service agreement for JOE Media and Lovin' Media also terminated. Iconic Labs noted that the agreements represented the most significant proportion of Iconic's revenue to date. The termination notices cited the resignation of Iconic's senior management team, with John Quinlan, Liam Harrington and Sam Asante all resigning due to the failure of European High Growth Opportunities Securitization Fund to accept a revised settlement offer as well as outstanding issues with OTT Holdings Ltd and Alpha Blue Ocean.

----------

Tiziana Life Sciences PLC - London-based therapeutics for oncology, inflammation and infectious diseases - Appoints Thomas Adams as an executive director. Adams will assume the position of head of Drug Development with immediate effect, and his executive role will be to manage and oversee the company's pre-clinical and clinical drug development programmes and associated intellectual property. He is currently a director at Hepion Pharmaceuticals Inc.

----------

All Active Asset Capital Ltd - London-based firm seeking investment opportunities in the technology, software and artificial intelligence space - Intends to appoint Colin McQuade as a non-executive director. He is currently chief technology officer for BGL Group Ltd, a financial services business specialising in home and vehicle insurance, and prior to this was head of Change Technology at Barclays International.

----------

CPPGroup PLC - Leeds-based insurance and financial services company - Says Nick Cooper will be stepping down from the board and his position as a non-executive director at the end of the month to focus on his executive role as general counsel & company secretary of Johnson Matthey PLC.

----------

Prairie Mining Ltd - Poland-focused coal development firm - Notified that Todd Hannigan will resign as an alternate director to Tom Todd on Friday as he concentrates on other business and investment opportunities. Tom Todd will continue to serve as a non-executive director.

----------

Record PLC - specialist currency manager - Says Bob Noyen, chief investment officer of Record Currency Management Ltd, has decided to step down from the board of Record to focus more on his day-to-day role, though his responsibilities remain unchanged and he will continue to serve on the board of Record Currency Management.

----------

Sensyne Health PLC - Oxford, England-based clinical technology company - Appoints Hina Zaman as managing director of Healthcare Division and Martin Gouldstone as chief business officer of Life Sciences Division. Zaman joins Sensyne from Babylon Health, while Gouldstone joins from Syneos where he was global SVP Capital Solutions at Syneos One.

----------

Wishbone Gold PLC - precious metals trading and exploration company with assets in Australia - Hires David Hutchins as non-executive director effective Friday. He is currently chair of the FTSE Gold Mines Index Committee.

----------

Intertek Group PLC - London-based quality assurance provider - Hires Lynda Clarizio as a non-executive direct effective March 1. She served as president of US Media at Nielsen Holdings PLC and is currently a director of CDW Corp, Emerald Holding Inc, Adjust GmbH, OpenSlate and Resonate Networks Inc. Louise Makin will be stepping down from the board as a non-executive director on June 30 after serving for nine years.

----------

Digitalbox PLC - Bath, England-based digital media business that owns The Daily Mash and The Tab - Says Non-Executive Nigel Burton has resigned with immediate effect in order to pursue other opportunities.

----------

Gulf Marine Services PLC - Abu Dhabi-founded provider of self-propelled self-elevating support vessels for oil, gas and renewable energy industries - Says Hassan Heikal has agreed to take up the role of deputy chair, having joined the board in November 2020 as a non-executive director. Jyrki Koskelo is joining the group as an independent non-executive director, with immediate effect, bringing "extensive additional business advisory experience" to the board. Koskelo is currently a board member, and chair of the investment committee, of the Africa Agriculture & Trade Investment Fund

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Dec 2019 15:38

Tiziana initiates study of 'Foralumab' in coated capsule form

(Sharecast News) - Clinical-stage biotechnology company Tiziana Life Sciences announced the initiation of a phase 1 clinical trial in healthy volunteers on Wednesday, with a proprietary oral formulation of 'Foralumab' encapsulated in enteric-coated capsules.

Read more
4 Dec 2019 11:52

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Read more
20 Nov 2019 13:02

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Read more
1 Nov 2019 17:31

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Read more
30 Sep 2019 10:27

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Read more
16 Sep 2019 13:03

Tiziana Life Sciences Gets New Foralumab Formulation US Trial Approval

(Alliance News) - Tiziana Life Sciences PLC on Monday said the US Food & Drug Adminsitration has allowed the company to begin a phase 1 clinical trial of its novel Foralumab formulation in in

Read more
10 Sep 2019 14:34

Tiziana Life Sciences Announces Positive Data From Foralumab Trial

(Alliance News) - Tiziana Life Sciences PLC on Tuesday said data from its phase 1 trial of Foralumab showed the drug "was well-tolerated at all doses" and produced a positive biomarker a

Read more
4 Sep 2019 11:04

Encouraging Data From Tiziana Life Sciences Milciclib Cancer Study

(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced positive data from its study of Milciclib in patients with advanced liver cancer.Shares in Tiziana were up 19% at 57.00 in

Read more
22 Jul 2019 09:54

Tiziana Reports No Drug-Related Deaths In Milciclib Liver Cancer trial

(Alliance News) - Tiziana Life Sciences PLC on Monday said there were no drug related deaths in its phase 2a trial of Milciclib in advanced liver cancer and the drug was well tolerated with some 6

Read more
1 Jul 2019 10:49

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith,

Read more
1 Jul 2019 10:20

Tiziana Notes Positive Study Of Drug Similar To Foralumab In Diabetes

(Alliance News) - Tiziana Life Sciences PLC on Monday noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes.Shares in the biotechnology company

Read more
1 May 2019 10:08

FDA asks Tiziana for more information on next 'foralumab' trial

(Sharecast News) - Biotechnology company Tiziana Life Sciences updated the market in its 'Investigational New Drug' (IND) application to the US Food and Drug Administration (FDA) on Wednesday, to initiate a phase 1 clinical trial of enteric-coated capsules of its 'foralumab' product in healthy volunteers.

Read more
24 Apr 2019 12:20

Most Patients Stick With Milciclib In Tiziana Life Sciences Study

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday reported encouraging interim data from its trial of milciclib in patients with advanced liver cancer.Shares in Tiziana were -

Read more
4 Apr 2019 10:58

Tiziana Life Sciences Annual Loss Narrows On Marginally Reduced Costs

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday reported a slight reduction in its annual loss as costs were reduced.For 2018, the clinical stage biotechnology company posted

Read more
20 Mar 2019 13:01

Tiziana Life Sciences Submits Application For Foralumab Trial In US

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it has submitted an application in the US to begin a phase one trial of its autoimmune and inflammatory disease drug new drug a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.